U.S. mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report By Type (Capping Agents, Nucleotides, Plasmid DNA, Enzymes), By Application (Vaccine Production, Therapeutics Production), By End Use, And Segment Forecasts, 2025 - 2033

出版社	出版年月	電子版価格	納期	ページ数	言語
Grand View Research グランドビューリサーチ	2025年7月21日	US$5,950 シングルユーザライセンス（印刷不可）ライセンス・価格情報注文方法はこちら	電子ファイル - ご注文後3営業日前後	90	英語

Table of Contents

Summary

U.S. mRNA Synthesis Raw Materials Market Summary

The U.S. mRNA synthesis raw materials market size was estimated at USD 541.0 million in 2024 and is projected to reach USD 932.2 million by 2033, growing at a CAGR of 6.57% from 2025 to 2033. This growth is attributed to the growing academic & industrial interest in mRNA technology, increasing funding for mRNA research, and rising awareness of the advantages of mRNA-based vaccines.

Moreover, the increasing therapeutic applications of RNA technology are anticipated to provide significant demand for the mRNA synthesis raw materials over the forecast period.

U.S. mRNA Synthesis Raw Materials Market Report Segmentation

This report forecasts revenue growth in the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. mRNA synthesis raw materials market report based on type, application, and end use:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Capping Agents
• CleanCap Reagents
• ARCA (Anti-Reverse Cap Analog)
• Others
• Nucleotides
• Modified Nucleic Acids
o N1-methylpseudouridine-triphosphate
o 5-Methylcytidine triphosphate (5mCTP)
o Others
• Natural Nucleic Acids
o Adenine
o Guanine
o Cytosine
o Uracil
• Plasmid DNA
• Enzymes
• Polymerase
• RNase Inhibitor
• DNase
• Others
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Vaccine Production
• Therapeutics Production
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Biopharmaceutical & Pharmaceutical Companies
• CROs & CMOs
• Academic & Research Institutes

ページTOPに戻る

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Type Segment
1.1.2. Application Segment
1.1.3. End Use Segment
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Primary Research
1.5. Information or Data Analysis:
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objective
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing academic & industrial interest in mRNA technology
3.2.1.2. Advantages of mRNA vaccines
3.2.1.3. Increasing funding for mRNA research
3.2.2. Market Restraint Analysis
3.2.2.1. Nonexistence of effective government regulations for mRNA-based product approvals
3.2.2.2. High cost of mRNA synthesis raw materials
3.2.3. Market Challenge Analysis
3.2.3.1. Lack of long-lasting and affordable manufacturing processes
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
Chapter 4. Type Business Analysis
4.1. Type Segment Dashboard
4.2. U.S. mRNA Synthesis Raw Materials Market Type Movement Analysis
4.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Capping Agents
4.4.1. Capping agents market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.2. CleanCap Reagents
4.4.2.1. CleanCap reagents market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3. ARCA (Anti-Reverse Cap Analog)
4.4.3.1. ARCA (anti-reverse cap analog) market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
4.5. Nucleotides
4.5.1. Nucleotides market estimates and forecasts, 2021 - 2033 (USD Million)
4.5.2. Modified Nucleic Acids
4.5.2.1. Modified nucleic acids market estimates and forecasts, 2021 - 2033 (USD Million)
4.5.2.2. N1-methylpseudouridine-triphosphate
4.5.2.2.1. N1-methylpseudouridine-triphosphate market estimates and forecasts, 2021 - 2033 (USD Million)
4.5.2.3. 5-Methylcytidine triphosphate (5mCTP)
4.5.2.3.1. 5-Methylcytidine triphosphate (5mCTP) market estimates and forecasts, 2021 - 2033 (USD Million)
4.5.2.4. Others
4.5.2.4.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
4.5.3. Natural Nucleic Acids
4.5.3.1. Natural nucleic acids market estimates and forecasts, 2021 - 2033 (USD Million)
4.5.3.2. Adenine
4.5.3.2.1. Adenine market estimates and forecasts, 2021 - 2033 (USD Million)
4.5.3.3. Guanine
4.5.3.3.1. Guanine market estimates and forecasts, 2021 - 2033 (USD Million)
4.5.3.4. Cytosine
4.5.3.4.1. Cytosine market estimates and forecasts, 2021 - 2033 (USD Million)
4.5.3.5. Uracil
4.5.3.5.1. Uracil market estimates and forecasts, 2021 - 2033 (USD Million)
4.6. Plasmid DNA
4.6.1. Plasmid DNA market estimates and forecasts, 2021 - 2033 (USD Million)
4.7. Enzymes
4.7.1. Enzymes market estimates and forecasts, 2021 - 2033 (USD Million)
4.7.2. Polymerase
4.7.2.1. Polymerase market estimates and forecasts, 2021 - 2033 (USD Million)
4.7.3. RNase Inhibitor
4.7.3.1. RNase inhibitor market estimates and forecasts, 2021 - 2033 (USD Million)
4.7.4. DNase
4.7.4.1. DNase market estimates and forecasts, 2021 - 2033 (USD Million)
4.7.5. Others
4.7.5.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
4.8. Others
4.8.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 5. Application Business Analysis
5.1. Application Segment Dashboard
5.2. U.S. mRNA Synthesis Raw Materials Market Application Movement Analysis
5.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Therapeutics Production
5.4.1. Therapeutics production market estimates and forecasts, 2021 - 2033 (USD Million)
5.5. Vaccine Production
5.5.1. Vaccine production market estimates and forecasts, 2021 - 2033 (USD Million)
5.6. Other Application
5.6.1. Other application market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 6. End Use Business Analysis
6.1. End Use Segment Dashboard
6.2. U.S. mRNA Synthesis Raw Materials Market End Use Movement Analysis
6.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Biopharmaceutical & Pharmaceutical Companies
6.4.1. Biopharmaceutical & pharmaceutical companies market estimates and forecasts, 2021 - 2033 (USD Million)
6.5. CROs & CMOs
6.5.1. CROs & CMOs market estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Academic & Research Institutes
6.6.1. Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2024
7.4. Company Profiles/Listing
7.4.1. F. Hoffmann-La Roche Ltd.
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Jena Bioscience GmbH
7.4.2.1. Overview
7.4.2.2. Product Benchmarking
7.4.2.3. Strategic Initiatives
7.4.3. Merck KGaA
7.4.3.1. Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd
7.4.4.1. Overview
7.4.4.2. Product Benchmarking
7.4.4.3. Strategic Initiatives
7.4.5. BOC Sciences
7.4.5.1. Overview
7.4.5.2. Product Benchmarking
7.4.5.3. Strategic Initiatives
7.4.6. Thermo Fisher Scientific, Inc.
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Maravai LifeSciences
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. New England Biolabs
7.4.8.1. Overview
7.4.8.2. Product Benchmarking
7.4.8.3. Strategic Initiatives
7.4.9. Creative Biogene
7.4.9.1. Overview
7.4.9.2. Product Benchmarking
7.4.9.3. Strategic Initiatives
7.4.10. HONGENE
7.4.10.1. Overview
7.4.10.2. Product Benchmarking
7.4.10.3. Strategic Initiatives
7.4.11. Evonik Industries AG
7.4.11.1. Overview
7.4.11.2. Financial Performance
7.4.11.3. Product Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. GENEVANT SCIENCES CORPORATION
7.4.12.1. Overview
7.4.12.2. Product Benchmarking
7.4.12.3. Strategic Initiatives

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

Grand View Research社の生物分野での最新刊レポート

本レポートと同じKEY WORD（agents）の最新刊レポート

よくあるご質問

Grand View Research社はどのような調査会社ですか?

グランドビューリサーチ（Grand View Research）は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。